Lin Lu left the country for Lianan New Selected Mixed Fund.
Yesterday, Guolian ‘an Fund Management Co., Ltd. announced that Lin Yun left Guolian’s new selection and mixing.
According to the data, Lin Lu worked as an analyst in the Institute of Guojin Securities Co., Ltd. from April 2011 to November 2014. In December 2014, he joined Guolianan Fund Management Co., Ltd. and successively served as researcher, assistant fund manager and fund manager.
Guolian Anxin Select Mix was established on March 4, 2014. As of August 31, 2022, the fund’s rate of return this year was -3.60%, and the rate of return since its establishment was 85.00%, with a cumulative net value of 1.7557 yuan.
Hongyi Yuanfang Fund appointed Ding Wang as Chief Information Officer and Zhang Jin as Deputy General Manager.
Today, Hongyi Yuanfang Fund Management Co., Ltd. announced that Ding Wang was appointed as the chief information officer; Zhang Jin is the deputy general manager.
According to the data, Ding Wang joined Hongyi Yuanfang Fund Management Co., Ltd. on July 1, 2022. Before joining Hongyi Yuanfang Fund Management Co., Ltd., he served as chief information officer and director of operation management department of Honeycomb Fund Management Co., Ltd., director of information technology department of Huachen Future Fund Management Co., Ltd., head of operation department of Ping An Russell Investment Management (Shanghai) Co., Ltd. and information technology manager of Xingzheng Global Fund Management Co., Ltd.
Zhang Jin joined Hongyi Yuanfang Fund Management Co., Ltd. on February 7, 2022. Before joining Hongyi Yuanfang Fund Management Co., Ltd., he served as deputy general manager and chief investment officer of Huatai Baoxing Fund Management Co., Ltd., general manager of investment management department, general manager of fixed income investment department, securities investment director of Huatai Asset Management Company, fund manager of Huaxia Fund Management Co., Ltd., and manager of self-operated business department of fund operation center.
Zhang Jin currently manages Hongyi Yuanfang State-owned Enterprise Transformation and Upgrading Mix A and Hongyi Yuanfang State-owned Enterprise Transformation and Upgrading Mix C. The fund was established on October 31, 2018 and September 10, 2021, respectively. As of August 31, 2022, the rate of return of the fund this year was -22.40% and -22.66%, and the rate of return since its establishment was 64.14% and -15.85%.
The first phase photovoltaic power generation project in Fukushima, Japan, a subsidiary of Shanghai Electric Power Company, was put into operation.
() Announcement: Recently, the Fukushima Phase I 76.5 MW photovoltaic power generation project invested and constructed by Shanghai Electric Power Japan Co., Ltd., a wholly-owned subsidiary of the company, was officially connected to the grid for power generation.
With a capacity of 76.5 MW, the project successfully passed the grid-connected test on August 27, 2022, and passed the inspection of the Ministry of Economy, Trade and Industry of Japan on September 1, and was officially connected to the grid for power generation. After putting into production, it is estimated that the average annual power generation will be 82.0617 million kWh, and the on-grid tariff including tax will be 44 yen/kWh. The commissioning of the first phase of Fukushima project is a good practice for the company to deepen the Japanese new energy market and participate in clean energy in developed countries, which is of positive significance for the company to further accelerate the clean and low-carbon transformation and achieve high-quality development.
Tongkun shares have been repurchased by 1.44%, with a total cost of 575 million yuan.
() Announcement was issued. As of August 31st, 2022, the company has repurchased 34,746,700 shares by centralized bidding, accounting for 1.4411% of the company’s total share capital. The highest purchase price was 18.00 yuan/share, and the lowest price was 13.90 yuan/share, with a total turnover of 575 million yuan.
Shanghai Electric Power: The first phase photovoltaic power generation project in Fukushima, Japan was put into operation.
Shanghai Electric Power announced on the evening of September 1 that recently, the 76.5 MW photovoltaic power generation project in Fukushima Phase I, which was invested and built by the company’s wholly-owned subsidiary, Japan Company, was officially connected to the grid for power generation. After the project is put into production, it is estimated that the average annual power generation will be 82,061,700 kWh, and the on-grid tariff including tax will be 44 yen/kWh.
Jinqiao Information spent RMB 32,822,900 to buy back 1.04% of the shares.
() Announcement was issued. By August 31st, 2022, the company had bought back 3,833,200 shares by centralized bidding, accounting for 1.04% of the company’s total share capital. The highest transaction price was RMB 9.60/share, the lowest transaction price was RMB 6.58/share, and the total paid funds were RMB 32,822,900 (excluding stamp duty, transaction commission and other related expenses).
Energy-saving wind power is allowed to issue green corporate bonds of no more than 2 billion yuan.
() Announcement. On August 31, 2022, the company received the Reply of China Securities Regulatory Commission on Agreeing to the Registration of China Energy Saving Wind Power Co., Ltd. to Publicly Issue Green Corporate Bonds to Professional Investors, and agreed to the company’s application for registration of publicly issuing green corporate bonds with a total face value of no more than 2 billion yuan to professional investors.
Huamao Technology has repurchased 1,997,700 shares at a cost of 56,411,100 yuan by the end of August.
() Announcement: As of August 31, 2022, the company has repurchased 1,997,700 shares of the company, accounting for 0.65% of the company’s total share capital. The highest price of the repurchase transaction is 30.49 yuan/share, and the lowest price is 25.00 yuan/share, with a total turnover of 56.411 million yuan (excluding transaction fees such as stamp duty and trading commission).
Aopu Home has repurchased 1.7556% of the shares and spent a total of 61,831,600 yuan.
() Announcement was issued. By August 31st, 2022, the company had repurchased 7,101,200 shares, accounting for 1.7556% of the company’s total share capital. The highest repurchase price was 10.02 yuan/share, and the lowest price was 7.82 yuan/share, and the total amount paid was 61,831,600 yuan.
Energy-saving wind power: the public offering of green corporate bonds was approved by CSRC.
Energy-saving wind power announced on the evening of September 1, the company received the approval from the China Securities Regulatory Commission, agreeing to the company’s registration application for publicly issuing green corporate bonds with a total face value of no more than 2 billion yuan to professional investors.
Zhejiang Longsheng spent 800 million yuan to buy back 2.3791% of the shares.
() Announcement was issued. As of August 31st, 2022, the company has repurchased 77,399,100 shares through centralized bidding, accounting for 2.3791% of the company’s total share capital. The highest price purchased is 10.68 yuan/share, and the lowest price is 9.85 yuan/share, and the total amount paid is 800 million yuan.
Sinopharm Hyundai: "Cefotaxime Sodium for Injection" was approved for marketing in Germany.
() Announcement. Recently, Dali Pharma GmbH ("Dali Pharma"), the controlling grandson of the company, received the marketing license of cefotaxime sodium for injection (0.5g, 1g and 2g) approved and issued by the German Federal Agency for Drugs and Medical Devices (BfArM).
It is reported that cefotaxime sodium is a third-generation semi-synthetic cephalosporin, which is generally used for infections of respiratory tract, urinary tract, bones and joints, skin and soft tissues, abdominal cavity, biliary tract, digestive tract, facial features and genitals caused by sensitive bacteria, and is also effective for infections caused by burns and trauma, sepsis and central infection.
Zhongkesoft spent 159 million yuan to buy back 1.1819% of the shares.
() Announcement was issued. As of August 31st, 2022, the company had repurchased 7,015,600 shares, accounting for 1.1819% of the company’s total share capital. The highest price of the repurchase transaction was 24.05 yuan/share, and the lowest price was 22.04 yuan/share. The total paid capital was 159 million yuan (excluding transaction fees such as commission).
Universal Scientific Industrial Co.，Ltd. bought back 8,175,300 shares at a cost of 104 million yuan.
() Announcement, the company has repurchased 8,175,300 shares of the company, accounting for about 0.37% of the company’s current total share capital. The highest price of the transaction was 14.22 yuan/share, the lowest price was 11.15 yuan/share, and the total transaction amount was 104 million yuan (excluding transaction costs).
Sellers: Sellers sold 10,045 vehicles in August, up 12.78% year-on-year.
On September 1st, the news () announced that the sales volume of new energy vehicles in August was 14,644, a year-on-year increase of 310.77%. Among them, the sales volume of Celestial vehicles was 10,045, a year-on-year increase of 1,277.91%.
Cyrus: In August, sales of Cyrus cars increased by 1,277.91% year-on-year.
Sellers announced on the evening of September 1st that the car sales in August were 20,371 vehicles, up 5.95% year-on-year. Among them, the sales volume of Celestial vehicles was 10,045, a year-on-year increase of 1,277.91%.
Liyuan Technology received an inquiry letter from the Shanghai Stock Exchange about the company’s application documents for issuing convertible bonds.
Liyuan Technology announced that on August 31st, 2022, the company received the "Inquiry Letter on Examination and Approval of Zhejiang Haiyan Liyuan Environmental Protection Technology Co., Ltd. to Issue Convertible Corporate Bonds to Unspecified Objects" issued by Shanghai Stock Exchange ("SSE"). The examination organization of SSE examined and approved the application documents submitted by the company to issue convertible bonds to unspecified objects, and formed the first round of inquiry questions, mainly involving several aspects: fundraising projects, financing scale and income calculation, and operating conditions (.
ST Panwei has repurchased 4.048 million shares at a cost of 147 million yuan.
() Announcement was issued. As of August 31st, the company had bought back 4.048 million shares by centralized bidding, accounting for 1.55% of the company’s total share capital. The highest transaction price was 4.135 yuan/share, the lowest transaction price was 30.75 yuan/share, and the total paid capital was 147 million yuan.
Xin Fengming spent 175 million yuan to repurchase 15,552,100 shares.
() Announced that from the start date of this repurchase to August 31, 2022, the company has repurchased 15,552,100 shares, accounting for 1.02% of the company’s total share capital, with the highest price of 12.61 yuan/share and the lowest price of 9.29 yuan/share, and the amount paid is 175 million yuan (excluding commission, transfer fees and other transaction costs).
The cumulative repurchase of 1.50% shares in 800 million time and space cost 59.9949 million yuan.
It was announced in 800 million hours. As of August 31, 2022, the company has repurchased 1,451,700 shares of the company through the trading system of Shanghai Stock Exchange by centralized bidding, accounting for 1.50% of the company’s total share capital. The highest price of the repurchase transaction is 44.15 yuan/share, and the lowest price is 35.41 yuan/share. The total amount of funds paid is 59,994,900 yuan (excluding transaction fees such as stamp duty and trading commission)
Baolande bought back 1.90% of the shares at a cost of 49.4443 million yuan.
Baolande announced that as of August 31st, 2022, the company had repurchased 1,063,100 shares of the company through the trading system of Shanghai Stock Exchange by centralized bidding, accounting for 1.90% of the company’s total share capital. The highest price of the repurchase transaction was 55.40 yuan/share, and the lowest price was 41.24 yuan/share. The total amount of funds paid was 49,444,300 yuan (excluding stamp duty, trading commission and other transactions)
By the end of August, Chunqiu Electronics’ repurchase ratio reached 1.36%, costing 59.99 million yuan.
() Announcement: As of August 31, 2022, the company has repurchased 5,986,700 shares, accounting for 1.3635% of the company’s total share capital. The highest price purchased is 11.44 yuan/share, and the lowest price is 9.11 yuan/share. The total amount paid (transaction amount) is 59,988,500 yuan.
The AITO series delivered 10,045 vehicles in August, and the monthly delivery exceeded 10,000 for the first time.
IT House reported on September 1 ST that this afternoon, Sailis (formerly Xiaokang) issued an announcement, revealing the company’s production and sales data in August 2022.
According to the announcement, there were 14,644 new energy vehicles in August, a year-on-year increase of 310.77%. Among them, the sales volume of Celestial vehicles was 10,045, a year-on-year increase of 1,277.91%.
In terms of output, Sailis Group produced 14,969 new energy vehicles in August, a year-on-year increase of 294.96%; Among them, the output of Celestial vehicles was 10,289, up 683.03% year-on-year.
The IT House understands that this also means that the delivery volume of AITO series in August reached 10,045 vehicles, and the monthly delivery volume exceeded 10,000 for the first time.
Among them, AITO Wenjie M5 officially started delivery to users on March 5, and WLTC has a battery life of over 1,000 kilometers. On August 24th, the delivery of the second model of Wenjie brand, Wenjie M7, was officially started, and it took only 51 days from listing to delivery.
In addition, the M5EV, the first pure electric vehicle in AITO, will also be officially released on September 6th.
Sinopharm Modern: Cefotaxime Sodium for Injection was approved for overseas listing.
On September 1st, Sinopharm announced that DALI Pharma, the controlling grandson of the company, received the marketing license of cefotaxime sodium for injection (0.5G, 1g, 2g) approved and issued by the German Federal Agency for Drugs and Medical Devices.
The cumulative repurchase ratio of Liantai Environmental Protection reached 1.26%, costing 47.1127 million yuan.
() Announcement: By the end of August, 2022, the company had repurchased 7,380,700 shares, accounting for 1.26% of the company’s total share capital. The highest price purchased was 6.91 yuan/share, and the lowest price was 5.68 yuan/share, and the total amount paid was 47,112,700 yuan (excluding transaction costs).
Huge group: 253 million shares of the company held by the original controlling shareholder will be auctioned.
() It was announced on the evening of September 1st. Recently, it received a notice from Beijing No.3 Intermediate People’s Court that in the case of civil execution between CDB Securities and Pang Qinghua, the former controlling shareholder of the company, and Tangshan Jidong Material Trade Group Co., Ltd., Beijing No.3 Intermediate People’s Court will dispose of 253 million shares of Pang Qinghua’s huge group stock, which will last from 10: 00 am on September 26th to 10: 00 am on September 27th, 2022 (except for the delay).
Three Gorges new materials received 6 million yuan from the central special fund for air pollution prevention and control.
() Announced, the company received 6 million yuan from the central air pollution prevention and control special fund for the environmental protection upgrade of the second line of float. At present, the company has received the above-mentioned special funds totaling 18 million yuan, which is a government subsidy related to assets, and is included in deferred revenue. It is estimated that the profit in 2022 will increase by 875,000 yuan.
Chengdu Gas: 10% of the state-owned shares of the controlling shareholder are transferred to the Sichuan Provincial Department of Finance free of charge.
() It was announced on the evening of September 1st. Recently, the company received a notice from Chengtou Group, the controlling shareholder: according to the Notice of Sichuan Provincial State-owned Assets Supervision and Administration Commission of Human Resources and Social Security Department of Sichuan Provincial Finance Department on Transferring Part of State-owned Capital of Chengdu State-owned Enterprises to Enrich Social Security Fund, it was decided to transfer 10% of the state-owned shares of Chengtou Group held by Chengdu State-owned Assets Supervision and Administration Commission to Sichuan Provincial Finance Department for free, and the industrial and commercial change registration has been completed recently. The transfer of state-owned shares will not lead to changes in the controlling shareholder and actual controller of the company. The controlling shareholder of the company is still Chengtou Group, and the actual controller is still Chengdu SASAC.
Chengdu Gas: Chengdu State-owned Assets Supervision and Administration Commission transferred 10% equity of Chengtou Group to Sichuan Provincial Department of Finance for free.
Chengdu Gas announced that recently, the company received a notice from the controlling shareholder Chengdu Urban Construction Investment Management Group Co., Ltd. ("Chengtou Group"): according to the requirements of the Notice of the Provincial State-owned Assets Supervision and Administration Commission of the Human Resources and Social Security Department of the Sichuan Provincial Department of Finance on Transferring Part of the State-owned Capital of Chengdu State-owned Enterprises to Enrich the Social Security Fund, it decided to transfer 10% of the state-owned shares of Chengtou Group held by Chengdu State-owned Assets Supervision and Administration Commission ("Chengdu State-owned Assets Supervision and Administration Commission") to the Sichuan Provincial Department of Finance for free, and has recently completed
Before this free transfer, Chengdu State-owned Assets Supervision and Administration Commission held 100% of the shares of Chengtou Group, which held 36.90% of the shares of the company as the controlling shareholder, and Chengdu State-owned Assets Supervision and Administration Commission was the actual controller of the company. After this free transfer, Chengdu SASAC holds 90.00% equity of Chengtou Group, Sichuan Provincial Department of Finance holds 10.00% equity of Chengtou Group, and Chengtou Group still holds 36.90% equity of the company; The controlling shareholder of the company is still Chengtou Group, and the actual controller is still Chengdu SASAC.
Guo Weisong, an intelligent forging company, reduced its shareholding by 1%, and the reduction was completed.
() Announcement was issued. As of August 31, 2022, Mr. Guo Weisong reduced his holdings of 4,944,100 shares of the company through centralized bidding, accounting for 1% of the company’s total share capital. This reduction plan was completed.
Zhang Dongye became vice chairman and general manager of Deye Co., Ltd.
() Announcement: The board of directors of the company recently received the written resignation of Zhang Hejun, the general manager of the company. Zhang Hejun applied to resign as the general manager of the company, and his resignation will take effect as of the date of delivery to the board of directors of the company. After resigning as general manager, Zhang Hejun still served as the chairman of the company and the chairman of the strategy Committee of the board of directors. In addition, on September 1, 2022, the board of directors of the company reviewed and approved relevant proposals, and unanimously agreed to elect Zhang Dongye as the vice chairman of the second board of directors of the company and appointed Zhang Dongye as the general manager of the company.
Health Yuan: GDR was issued and listed on the Swiss Stock Exchange and approved by the China Securities Regulatory Commission.
() On the evening of September 1st, the company recently received a reply from the China Securities Regulatory Commission, approving that the number of new A-share basic shares corresponding to the issuance of global depositary receipts ("GDR") by the company should not exceed 186 million shares. According to the conversion ratio determined by the company, the number of GDR issued should not exceed 18,615,800 shares. After the issuance, the company can be listed on the Swiss Stock Exchange.
Health Yuan issued GDR and listed on Swiss Stock Exchange, which was approved by China Securities Regulatory Commission.
Health Yuan Announcement: Recently, the company received the Reply of China Securities Regulatory Commission ("China Securities Regulatory Commission") on Approving the Initial Public Offering of Global Depositary Receipts by Health Yuan Pharmaceutical Group Co., Ltd. and Listing on Swiss Stock Exchange.
According to the reply, the China Securities Regulatory Commission approved that the number of newly-added A-share base shares corresponding to the issuance of Global Depository Receipts ("GDR") by the company should not exceed 186 million shares, and the number of GDR issuance should not exceed 18,615,800 according to the conversion ratio determined by the company. If the conversion ratio is adjusted, the number of GDR issues can be adjusted accordingly. After the completion of this issuance, the company can be listed on the Swiss Stock Exchange.
Huiyu Pharmaceutical: Azacytidine for injection was approved for marketing in Italy.
On September 1st, Huiyu Pharmaceutical announced that Seacross Pharma(Europe)Limited, a wholly-owned subsidiary, recently received a marketing license for azacytidine for injection from the Italian Food and Drug Administration.
Hokuriku Pharmaceutical set up a wholly-owned R&D subsidiary to create the second growth curve.
() Announced that in order to further improve the company’s R&D system, enhance its R&D strength, create a second growth curve, and realize the development goal of becoming a "Top 100 Pharmaceutical Enterprises in China", the company established a wholly-owned subsidiary Beijing Beilu Yikang Pharmaceutical R&D Co., Ltd. with its own capital of 10 million yuan. Recently, Beijing Beiliu Yikang Pharmaceutical R&D Co., Ltd. completed the industrial and commercial registration registration and obtained the Business License issued by Changping District Market Supervision Administration of Beijing.
The company has decided to select cardiovascular and cerebrovascular systems, digestive systems and nervous (mental) systems (chemical drugs) with large market demand as the key project areas in order to solve the clinical needs, in addition to the contrast agent field, central nervous system field (Chinese patent medicine) and endocrine field. The company set up a wholly-owned subsidiary, Beilu Yikang, and established a brand-new R&D system with R&D center and enterprise development department (BD). Three relatively independent and collaborative R&D institutions will greatly enhance the company’s R&D strength.
Huatie Emergency plans to jointly invest 100 million yuan with Dongyang Chengtou to set up a joint venture company.
() Announced that the Company and Dongyang Chengtou signed the Shareholders’ Agreement of Zhejiang Chengtou Huatie Engineering Equipment Leasing Co., Ltd. on September 1, 2022, and planned to jointly set up a joint venture company to carry out construction machinery and equipment leasing business. The registered capital of the joint venture company is 100 million yuan, of which the company has subscribed 49 million yuan, accounting for 49% of the shares, and Dongyang City Investment has subscribed 51 million yuan, accounting for 51% of the shares.
In order to speed up the layout of light assets strategy, the company and Dongyang Chengtou plan to jointly invest in the establishment of a joint venture company, Chengtou Huatie. With the company’s rich industry experience, perfect service network and professional talent team, combined with Dongyang Chengtou’s advantages in capital, policy and resource channels, it will build a benchmark project for light assets cooperation and achieve a win-win situation. After the establishment of the joint venture company, Dongyang Chengtou is responsible for actively raising funds, and the company is responsible for operation and management. This model effectively reduces the dependence on capital investment in the company’s development and conforms to the company’s long-term development and overall strategy.
Bohui Paper has repurchased 75.57 million shares at a cost of 822 million yuan.
() Announcement was issued. As of August 31st, the company has bought back 75.57 million shares by centralized bidding, accounting for 5.65% of the company’s total share capital. The highest transaction price was 19.62 yuan/share, the lowest transaction price was 6.70 yuan/share, and the total amount paid was 822 million yuan.
Xing Boyue, the actual controller of Jinhua, completed the increase of 2.33% of the shares.
() Announcement: From April 13th to September 1st, 2022, Xing Boyue, the company’s director and actual controller, accumulated 8,705,900 shares of the company, accounting for 2.33% of the company’s total share capital. The cumulative increase in holdings has exceeded the lower limit of the stock increase plan, and this increase plan has been implemented.
By the end of August, Bafang shares had repurchased 303,400 shares at a cost of 54,571,500 yuan.
() Announcement: As of August 31, 2022, the cumulative number of shares repurchased by the company was 303,400 shares, accounting for about 0.2522% of the total share capital. The highest transaction price was 1.9535 yuan/share, the lowest transaction price was 147.21 yuan/share, and the total turnover was 54.5715 million yuan (excluding transaction costs).
Kaisai Bio has repurchased 957,000 shares at a cost of 82,773,700 yuan.
Kaisai Bio announced that as of August 31, 2022, the company had repurchased 957,000 shares of the company through the trading system of Shanghai Stock Exchange by centralized bidding, accounting for 0.1641% of the company’s total share capital. The highest price of the repurchase transaction was 103.29 yuan/share, and the lowest price was 69.33 yuan/share. The total amount of funds paid was 82,773,700 yuan (excluding stamp duty and trading commission, etc.)
Antu Bio has repurchased 5,220,900 shares at a cost of 241 million yuan.
() Announcement was issued. As of August 31st, the company has repurchased 5,220,900 shares through centralized bidding, accounting for 0.8905% of the company’s total share capital. The highest price of the transaction was 49.92 yuan/share, and the lowest price was 42.32 yuan/share, and the total amount paid was 241 million yuan.
Huatie Emergency: It is planned to invest 49 million yuan to set up a joint venture company with Dongyang Chengtou.
Huatie Emergency announced on the evening of September 1 that the company and Dongyang Chengtou signed the Shareholders’ Agreement of Zhejiang Chengtou Huatie Engineering Equipment Leasing Co., Ltd., and planned to jointly set up a joint venture company, Chengtou Huatie, to carry out construction machinery and equipment leasing business. The registered capital of the joint venture company is 100 million yuan, of which the company has subscribed 49 million yuan, accounting for 49% of the shares. This time, a joint venture company will be established with Dongyang Chengtou, and both parties will actively explore new models of equipment leasing industry based on innovative technologies such as IOT and blockchain.
Xin qi Wei Zhuang: it is planned to raise no more than 825 million yuan.
On the evening of September 1st, Xinqi Micro-assembly announced that the total amount of funds raised by the company to issue shares to specific targets should not exceed 825 million yuan. After deducting the issuance expenses, it will be used for deepening and expanding the application of direct writing lithography equipment industry, IC carrier board and class carrier board direct writing lithography equipment industrialization projects, independent research and development projects of key subsystems and core components, and supplementary liquidity projects.
Weir shares: Extension of the fundraising project "Wafer Testing and Wafer Reconstruction Production Line Project (Phase II)"
() Announcement: The investment project "Wafer Testing and Wafer Reconstruction Production Line Project (Phase II)" raised by the company was originally planned to reach the scheduled usable state in May 2022. Recently, due to the influence of epidemic situation and other factors, the debugging progress of the company’s equipment acceptance production line slowed down, resulting in the project’s progress falling behind the original progress. Under the condition that the investment content, investment purpose, total investment and implementer of the project will not change, the date when the project reaches the scheduled usable state will be postponed. It is estimated that the "Wafer Testing and Wafer Reconstruction Production Line Project (Phase II)" will reach the scheduled usable state in October 2022.
Cinda Real Estate: The subsidiary intends to participate in the subscription of partnership shares to invest in a project in Wuhan area.
() On the evening of September 1st, it was announced that Anhui Xinda Real Estate, a wholly-owned subsidiary of the company, China Xinda, a related party of the company, and Xinda Capital, a subsidiary of the company, jointly subscribed for the share of the partnership. The total subscription scale of the partnership is 5.391 billion yuan, of which China Cinda, as a limited partner, subscribed 2.82 billion yuan, accounting for 52.31% of the partnership scale; As a limited partner, Anhui Xinda Real Estate subscribed 500 million yuan with its own funds, accounting for 9.27% of the partnership scale, and provided development and construction management services for the project. The partnership intends to invest in a project in Wuhan. As of January 24th, 2022, the appraisal value of the land involved in this investment is about 4.3 billion yuan.
The controlling shareholder of Swan Co., Ltd. pledged 6.461 million shares and 6.54 million shares of supply and marketing capital.
() Announcement was issued. On September 1, 2022, the company received the Letter of Notification from the controlling shareholder’s supply and marketing capital. The 6,461,000 shares pledged by the supply and marketing capital to Shanxi Securities Co., Ltd. (hereinafter referred to as "Shanxi Securities") expired on August 31, 2022, and the 6,540,000 shares held by the company were pledged to Shanxi Securities on September 1, 2022.
8.19 million restricted shares of SDIC Zhonglu will be listed and circulated on September 7th.
() Announced that the number of tradable shares restricted by share reform is 8.19 million shares, and the listing date is September 7, 2022. After this listing, the remaining number of shares restricted for sale is 0 shares.
Daheng Technology intends to sell some land use rights and above-ground buildings located in Beijing.
() Announce that in order to implement the business strategy of focusing on the main business, revitalizing inefficient assets and further supporting the development of the main business, the company plans to sell the land with a use right area of 12,619.87 square meters and the house with a building area of 5,248.27 square meters located in Science City 11-C, Fengtai District, Beijing. The company will refer to the market price and determine the final transaction price according to the actual needs of the company and other factors.
Deye shares: Zhang Dongye is the vice chairman and general manager.
Deye shares today announced the resignation of the general manager, the election of the vice chairman and the appointment of the general manager.
The board of directors of the company recently received the written resignation of Zhang Hejun, the general manager of the company. Due to the needs of the company’s business development, Zhang Hejun applied to resign as the general manager of the company. According to the Company Law of People’s Republic of China (PRC), the Articles of Association of Ningbo Deye Technology Co., Ltd. and other relevant regulations, Zhang Hejun’s resignation will take effect from the date when it is delivered to the board of directors of the company. After resigning as general manager, Zhang Hejun still served as the chairman of the company and the chairman of the strategy Committee of the board of directors.
Today, the company held the 16th meeting of the second board of directors, deliberated and passed the Proposal on Electing the Vice Chairman of the Second Board of Directors, and unanimously agreed to elect Zhang Dongye as the Vice Chairman of the Second Board of Directors, with a term of office from the date of deliberation and approval of the second board of directors to the date of expiration of the second board of directors.
Due to the needs of the company’s business development, it was nominated by the chairman of the company and approved by the Nomination Committee of the second board of directors. On September 1, 2022, the company held the 16th meeting of the second board of directors, reviewed and approved the Proposal on Appointing the General Manager of the company, and unanimously agreed to appoint Zhang Dongye as the general manager of the company, with a term of office from the date of deliberation and approval by the board of directors to the date of expiration of the second board of directors. At the same time, Zhang Dongye will automatically no longer serve as the deputy general manager of the company.
Resume of Zhang Dongye:
Zhang Dongye, born in 1981, Canadian nationality, bachelor degree. From December 2006 to July 2019, he served as a director of Deye (Hong Kong) Electrical Technology Co., Ltd.; Since July 2010, he has served as deputy general manager, director and current general manager of Ningbo Deye Daily Electrical Appliance Technology Co., Ltd.; From July 2016 to March 2019, he served as a director of Virgin Hengli Co., Ltd.; From September 2018 to December 2020, he served as a director of Deye Japan Co., Ltd.; Since April 2005, he has served as the sales director and deputy general manager of the company, and is currently the vice chairman and general manager of the company.
As of the disclosure date of the announcement, Zhang Dongye does not hold the company’s stock, and is the son of Zhang Hejun, the actual controller of the company.
Xingtong Co., Ltd. plans to set up Sun Company in Singapore to expand the international transportation of liquid goods and dangerous goods.
() Announcement: In order to meet the needs of international transportation of dangerous liquid goods, the company plans to set up a wholly-owned Sun Company "Xingtong Shipping (Singapore) Co., Ltd." ("Xingtong Singapore") in Singapore through its wholly-owned subsidiary Xingtong Shipping (Hainan) Co., Ltd. ("Xingtong Singapore"), with a total investment of no more than US$ 35 million. After its establishment, it plans to mainly engage in international transportation of dangerous liquid goods and refined oil products, ship management and so on.
176 million restricted shares of Power Xinke will be listed and circulated on September 7th.
() Announced that the number of restricted shares listed and circulated by the company this time is 176 million shares, accounting for 10.77% of the company’s total share capital, and the listing and circulation date is September 7, 2022.
Tian Sanhong, a shareholder of Valin Seiko, reduced his holdings by 1.33 million shares.
() Announcement: Tian Sanhong, the shareholder of the company, traded 1.33 million shares through centralized bidding, accounting for 1% of the company’s total share capital.
China xd subsidiary consortium signed a $663 million overseas contract.
() Announcement: Recently, a consortium of Xidian International, a wholly-owned subsidiary of the company, and China Southern Power Grid International Co., Ltd. signed an EPC project contract for Kilo HVDC converter station in Chile with Conexió n Kimallo Aguirre S.A. The winning contract amount was 663 million US dollars, of which Xidian International undertook a contract amount of 426 million US dollars, equivalent to about 2.9 billion yuan, accounting for about 20% of the company’s audited operating income in 2021.
Xingtong Co., Ltd. plans to spend 206 million yuan to buy a domestic chemical ship "Fenghai 32"
Xingtong shares announced that in order to enhance the capacity scale and market competitiveness of the company, the company plans to purchase the domestic chemical ship "Fenghai 32" under its name from Dongguan Fenghai Shipping Co., Ltd. for RMB 206 million (including 3% value-added tax), with a carrying capacity of 27,356 tons. The sources of funds for this ship purchase are raised funds, self-owned funds and bank loans.
China xd: The subsidiary signed the EPC project contract of Kilo HVDC converter station in Chile.
China xd announced on the evening of September 1st that recently, a consortium of Xidian International, a wholly-owned subsidiary of the company, and China Southern Power Grid International Co., Ltd. signed an EPC project contract for Kilo HVDC converter station in Chile with CONEXIóN KIMAL LOAGUIRRE S.A The winning contract amount was 664 million US dollars, of which Xidian International undertook a contract amount of 426 million US dollars, equivalent to about 2.9 billion yuan, accounting for about 20% of the company’s audited operating income in 2021.
China xd: The consortium affiliated to the subsidiary signed the EPC project contract of Kilo HVDC converter station in Chile.
China xd announced on the evening of September 1st that recently, a consortium of Xidian International, a wholly-owned subsidiary of the company, and China Southern Power Grid International Co., Ltd. signed an EPC project contract for Kilo HVDC converter station in Chile with CONEXIóN KIMAL LOAGUIRRE S.A The winning contract amount was 664 million US dollars, of which Xidian International undertook a contract amount of 426 million US dollars, equivalent to about 2.9 billion yuan, accounting for about 20% of the company’s audited operating income in 2021.
China xd: The consortium signed the EPC project contract of 664 million USD HVDC converter station.
On September 1st, china xd announced that a consortium of wholly-owned subsidiaries, Xidian International and China Southern Power Grid International Co., Ltd., signed an EPC project contract for Kilo HVDC converter station in Chile with CONEXIóN KIMAL LOAGUIRRE S.A The winning contract amount was 664 million US dollars, of which Xidian International undertook a contract amount of 426 million US dollars, equivalent to about 2.9 billion yuan, accounting for about 20% of the company’s audited operating income in 2021.
By the end of August, the repurchase ratio of Yu Xiang Medical reached 1.42%, costing 73.27 million yuan.
Yu Xiang Medical announced that as of August 31, 2022, the company had repurchased 2,274,500 shares of the company, accounting for 1.4216% of the company’s total share capital. The highest price of the repurchase transaction was 3450 yuan/share, and the lowest price was 28.27 yuan/share. The total amount of funds paid was 73,270,300 yuan (excluding transaction fees such as trading commission and transfer fees).
Shandong Huapeng intends to transfer 100% equity and internal creditor’s rights of Jiangsu Shidao by listing.
() Announce that in order to further revitalize assets and focus on the development of main business, the company intends to transfer 100% equity and internal creditor’s rights of Jiangsu Shidao by public listing through Shandong Property Rights Exchange Center. The listing price of the equity and internal creditor’s rights to be transferred this time is determined based on the evaluation value.
Hengrui Pharma: HRG2101 inhalation will be used in clinical trials of idiopathic pulmonary fibrosis.
() Announcement: The company has received the Notice of Approval for Clinical Trials of Drugs for HRG2101 Inhalation from National Medical Products Administration, and will conduct clinical trials (for idiopathic pulmonary fibrosis) in the near future.
The announcement shows that HRG2101 inhibits the biological activity of fibroblasts and reduces cell proliferation and matrix collagen synthesis by regulating or inhibiting cytokines such as TGF-β1. At the same time, it can also inhibit the secretion of inflammatory mediators such as TNF-α, reduce lipid peroxidation, and exert its anti-inflammatory and antioxidant effects.
Hengrui Pharma: HRG2101 inhalation was approved for clinical trial of idiopathic pulmonary fibrosis.
Hengrui Pharma announced that recently, the company received the Notice of Approval for Clinical Trials of Drugs for HRG2101 Inhalation from National Medical Products Administration ("National Medical Products Administration"), and National Medical Products Administration agreed to carry out clinical trials for idiopathic pulmonary fibrosis, which will be carried out in the near future.
It is reported that HRG2101 inhibits the biological activity of fibroblasts and reduces cell proliferation and matrix collagen synthesis by regulating or inhibiting cytokines such as TGF-β1. At the same time, it can also inhibit the secretion of inflammatory mediators such as TNF-α, reduce lipid peroxidation, and exert its anti-inflammatory and antioxidant effects. Upon inquiry, at present, no similar products of domestic enterprises have been approved for listing, and there is no relevant sales data.
Yuejian Intelligent has received compensation of 387 million yuan for all house demolition.
() Announce, as of the disclosure date of this announcement, the company has completed this demolition, and the company has received all compensation for this demolition agreement, totaling RMB 387 million.
In August, the subsidiary of Far East Co., Ltd. won the bid of more than 10 million yuan, totaling 2.687 billion yuan.
Far East announced that in August, 2022, the company received a total of RMB 2.687 billion (accounting for 12.87% of the company’s audited revenue in 2021 and 10.33% of the revenue plan in 2022) from its subsidiaries, which will have a positive impact on the company’s future business performance, but will not affect the company’s business independence.
Hengrui Pharma: Sevoflurane for inhalation obtained drug registration certificate.
Hengrui Pharma announced that the company had received the Drug Registration Certificate approved and issued by National Medical Products Administration, and the related drugs were sevoflurane for inhalation. The approved indication is: "This product is suitable for the induction and maintenance of general anesthesia in adults and children." The company’s approval this time is deemed to have passed the consistency evaluation of generic drug quality and efficacy.
Neusoft Group repurchased 12.4488 million shares at a cost of 137 million yuan.
() Announcement was issued. As of August 31, 2022, the company repurchased 12,448,800 shares through centralized bidding, accounting for 1.00% of the company’s current total share capital, an increase of 0.01% compared with the last disclosure. The highest price of the repurchase transaction is 11.92 yuan/share, the lowest price is 10.30 yuan/share, and the total paid funds are 137 million yuan (excluding transaction costs such as stamp duty and commission).
Hang Seng Electronics has spent 53.51 million yuan to buy back 1.3 million shares.
() Announced that by the end of August 2022, the company had repurchased 1.3 million shares, accounting for 0.0684% of the company’s total share capital. The lowest price was 34.33 yuan/share, the highest price was 46.93 yuan/share, and the total amount paid was 53.51 million yuan.
Far East shares: In August, the total number of orders won/signed by subsidiaries was 2.687 billion yuan.
Far East announced on the evening of September 1 that in August, the company received a total of 2.687 billion yuan of contract orders from its subsidiaries that won the bid/signed more than 10 million yuan, accounting for 12.87% of the company’s audited revenue in 2021 and 10.33% of its revenue plan in 2022 respectively.
Ge Min, Chief Operating Officer of Jinchen Co., resigned.
() Announcement: The board of directors of the company recently received a resignation report from Mr. Ge Min, the chief operating officer of the company. Mr. Ge Min applied to resign as the chief operating officer of the company for personal reasons. After his resignation, Mr. Ge Min will no longer hold any positions in the company and its holding subsidiaries.
By the end of August, Haizheng Pharmaceutical’s repurchase ratio reached 1.3%, costing 185 million yuan.
() Announcement: As of August 31, 2022, the company has repurchased 15.631 million shares, accounting for 1.3046% of the company’s total share capital, with the highest price of 1.299 yuan/share and the lowest price of 9.896 yuan/share, and the total amount paid is 185 million yuan (excluding transaction costs).
Kailuan Group, the controlling shareholder of kailuan shares, intends to increase its shareholding by no more than 2%.
() Announced that Kailuan Group, the controlling shareholder, increased its holding of 68,500 shares of the company by centralized bidding through the trading system of Shanghai Stock Exchange on September 1, 2022, accounting for 0.0043% of the company’s total share capital; It is also planned that within 12 months from the date of this increase, the cumulative number of shares of the company (including this increase) will not exceed 2% of the company’s total share capital.
Jiuzhoutong has repurchased 32.49 million shares at a cost of 384 million yuan.
() Announced that as of August 31st, the company had repurchased 32.49 million shares, accounting for 1.73% of the company’s total share capital, and the total amount paid was 384 million yuan.
Hengrui Pharma: Notice of Approval of HRG2101 Inhalation for Drug Clinical Trial
Hengrui Pharma announced on the evening of September 1st that the company had received the Notice of Approval for Clinical Trials of Drugs for HRG2101 Inhalation from National Medical Products Administration, and would conduct clinical trials in the near future. Sevoflurane for drug inhalation received the Drug Registration Certificate approved and issued by National Medical Products Administration.
By the end of August, Chint had repurchased 21.3045 million shares at a cost of 1.045 billion yuan.
() Announcement: As of August 31, 2022, the company has repurchased 21,304,500 shares, accounting for 0.9909% of the company’s total share capital. The highest price of repurchase is 54.00 yuan/share, and the lowest price is 31.80 yuan/share, with a total turnover of 1.045 billion yuan (excluding transaction costs).
Kailuan shares: The controlling shareholder intends to increase its shareholding by no more than 2%.
Kailuan shares announced on the evening of September 1st that Kailuan Group, the controlling shareholder of the company, increased its holding of 68,500 shares by centralized bidding on September 1st, accounting for 0.0043% of the company’s total share capital. It is also planned that within 12 months from the date of this increase, the cumulative number of shares of the company (including this increase) will not exceed 2% of the company’s total share capital.
Samsung Medical won the bid of 330 million yuan to purchase the pre-installed substation project of wind, light and photovoltaic.
() It was announced that Ningbo Oaks High-tech Co., Ltd. (hereinafter referred to as "Oaks High-tech"), a subsidiary of the company, was recently recommended as a candidate for winning the bid in the 2022-2023 framework procurement of photovoltaic pre-installed substation (Chinese-style, oil transformer) project of China Datang Group Co., Ltd., with an estimated bid amount of about 330 million yuan.
Health Yuan: The issuance of GDR and its listing on the Swiss Stock Exchange were approved by the China Securities Regulatory Commission.
Health Yuan Announcement: The company received the reply from China Securities Regulatory Commission, and approved that the number of newly-added A-share base shares corresponding to the issuance of global depositary receipts (hereinafter referred to as "GDR") should not exceed 186,158,099. According to the conversion ratio determined by the company, the number of GDR issues should not exceed 18,615,809. After the completion of this issuance, the company can be listed on the Swiss Stock Exchange.
Far East shares: In August, more than 10 million orders were received, a year-on-year increase of 135.19%.
On September 1st, Far East announced that in August, 2022, the company received a total of RMB 2.687 billion from its subsidiaries, up 135.19% year-on-year and 73.51% quarter-on-quarter. From January to August, the company received a total of 15.233 billion yuan from its subsidiaries, with a year-on-year increase of 27.77%.
Among them, in the intelligent cable network sector, from January to August, the accumulated contract orders of winning the bid/signing more than 10 million yuan were 13.934 billion yuan, up 56.12% year-on-year, of which the contract orders of winning the bid/signing more than 10 million yuan in August were 2.434 billion yuan, up 172.81% year-on-year and up 58.78% quarter-on-quarter.
In the smart battery sector, from January to August, the cumulative bid/contract orders of more than 10 million yuan were 539 million yuan, of which the bid/contract orders of more than 10 million yuan in the lithium battery business were 416 million yuan, accounting for 78.85% of household energy storage orders.
In the smart airport sector, from January to August, the cumulative number of contract orders that won the bid/signed more than 10 million yuan was 760 million yuan, of which the number of contract orders that won the bid/signed more than 10 million yuan in August was 253 million yuan, up 21.50% year-on-year and 1,531.91% quarter-on-quarter. (Qin Sheng)
*ST Kaile signed an agreement with the controlling shareholder Keda Trading to reduce the company’s losses.
() Announcement: On January 14th, 2022, the Company, Hunan Kaile Emergency Information Technology Co., Ltd. ("Hunan Kaile"), Jingzhou Keda Trading Co., Ltd. ("Keda Trading") and Zhuzhou Gaoxin Power Industry Investment and Development Co., Ltd. ("Zhuzhou Gaoxin") reached a mediation agreement under the mediation of Zhuzhou Intermediate People’s Court. According to the Civil Mediation, the Company, Hunan Kaile and Keda Trading (the "Debtor") jointly confirmed that the loan owed to Zhuzhou Gaoxin totaled 1.093 billion yuan, which was jointly repaid by the Debtor and paid in installments, of which the first payment of 20 million yuan was deducted from the frozen bank account of Kaile Technology.
It is reported that the company was deducted by the court from freezing basic deposit account to pay Zhuzhou Hi-tech, which does not belong to the situation that the company voluntarily repays for the controlling shareholder Keda Trading. In order to reduce the losses of listed companies, the company conducted friendly consultations with Keda Commerce and Trade, and unanimously agreed that in the case that the repayment ratio of the three parties to the debt was not stipulated in the Civil Mediation, the three parties to the debt should bear the corresponding debts equally. The company recently signed an agreement with Keda Trading.
Referring to the relevant judicial practice of the guarantee rules, the two parties reached the following agreement through consultation: 1. Keda Trading paid RMB 6,666,666.67 to the company; 2. In view of the fact that the bank account of Keda Trading is currently frozen, the above payment shall be paid immediately after the account of Keda Trading is unsealed; 3. The above-mentioned debt of 1.093 billion yuan shall be borne by Keda Trading, Kaile Technology and Hunan Kaile each with one third of the responsibility. If Kaile Technology undertakes the repayment responsibility alone, Keda Commerce promises to pay one third of the paid amount to Kaile Technology or transfer assets with the same value.
According to the announcement, the company signed the Agreement with Keda Trading, aiming at clarifying the repayment responsibilities of Keda Trading, Kaile Technology and Hunan Kaile, reducing the losses of listed companies and safeguarding the rights and interests of the company. The above amount forms a passive capital occupation of the company by Keda Trading.
Energy-saving wind power: the public offering of green corporate bonds was approved by CSRC.
Energy-saving wind power announcement, the company received a reply from the China Securities Regulatory Commission, agreeing to the company’s registration application for publicly issuing green corporate bonds with a total face value of no more than 2 billion yuan to professional investors.
Minghua, the shareholder of Ganli Pharmaceutical, reduced its shareholding by 1.10%.
() Announcement. Recently, the company received a written notice from Minghua Innovation. From May 23, 2022 to August 31, 2022, Minghua Innovation reduced its holdings of 6,189,600 shares by centralized bidding, accounting for 1.10% of the company’s total share capital.
Ganli Pharmaceutical GZR4 China Phase I clinical trial completed the first administration to subjects.
Ganli Pharmaceutical announced that GZR4, which was independently developed by the company, is conducting a phase I clinical trial in China, and recently successfully completed the first drug administration to subjects. GZR4 is an ultra-long-acting insulin weekly preparation which is administered subcutaneously once a week and is being researched by Ganli Pharmaceutical Co., Ltd., and its indication is diabetes.
Pengshan Xincheng, the shareholder of Le Kai Film, has reduced its holdings by 11.065 million shares.
() Announcement was issued. As of the disclosure date of this report, Pengshan Xincheng’s reduction plan has been completed. From June 1 to August 31, 2022, Pengshan Xincheng reduced its shareholding by 5,532,500 shares through centralized bidding, accounting for 1.00% of the company’s total share capital; During the period from March 1 to August 31, 2022, Pengshan Xincheng reduced its holdings by 11.065 million shares through centralized bidding, accounting for 2.00% of the company’s total share capital. This reduction plan was completed.
Ganli Pharmaceutical Co., Ltd.: China Phase I clinical trial of GZR4 completed the first administration to subjects.
Ganli Pharmaceutical announced on the evening of September 1st that GZR4 independently developed by the company is conducting phase I clinical trials in China, and recently successfully completed the first drug administration to subjects. GZR4 is an ultra-long-acting insulin weekly preparation which is administered subcutaneously once a week and is being researched by Ganli Pharmaceutical Co., Ltd., and its indication is diabetes.
Yulong shares: It is planned to invest 5 million Australian dollars to subscribe for private placement shares of Cuiteng Mining.
() On the evening of September 1st, it was announced that the company and Cuiteng Mining intend to sign the Placement Investment Intention Form, and the company (or its subsidiaries) intend to invest 5 million Australian dollars to subscribe for private placement shares of Cuiteng Mining, and the subscription price is 0.029 Australian dollars per share, which is lower than the weighted average price of the volume of Cuiteng Mining in the 20 trading days before signing the Placement Investment Intention Form. Cuiteng Mining is committed to the exploration and exploitation of graphite mine projects, and holds graphite mineral rights in Ankwabe, Baramabei and Baramanan in Cabo Delgado province in northern Mozambique, Africa.
Yulong Co., Ltd. plans to subscribe for 5 million Australian dollars for the fixed share of Cuiteng Mining, which owns several graphite mines.
Yulong shares announced that the company and Cuiteng Mining intend to sign the Placement Investment Intention Form, and the company (or its subsidiaries) intends to invest 5 million Australian dollars to subscribe for private placement shares of Cuiteng Mining at a subscription price of 0.029 Australian dollars per share, which is lower than the weighted average price of Cuiteng Mining’s trading volume in the 20 trading days before signing the Placement Investment Intention Form.
According to the announcement, Cuiteng Mining holds Ankwabe graphite mine, Baramabei graphite mine and Baramanan graphite mine in Cabo Delgado province in northern Mozambique, Africa. Among them, Ankwabe graphite mine project is a large and super-large scale graphite mine, including T12 and T16 resources. According to the research report on Ankwabe graphite issued by Lycopodium Minerals Pty Limited, CSA Global Pty Limited and other institutions, the project has about 46.1 million tons of graphite mine resources meeting JORC standards, and its recoverable reserves are 24.895 million tons. The recoverable reserves in T16 mine area are 11.17 million tons, with an average fixed carbon grade of 7. The recoverable reserves of T12 mining area are 13.725 million tons, with an average fixed carbon grade of 5.32%. The environmental permit of Ankwabe graphite project has been approved by government departments. The feasibility study (DFS) of the project was completed in December 2017, and the mining permit was obtained in June 2019 with a term of 25 years. Parama North and Parama South graphite mine projects are still in the stage of resource exploration. None of the above graphite mine projects has been put into production.
According to the announcement, this transaction is conducive to the company’s integration of the internal resources of the controlling shareholder, empowering the high-quality development of listed companies, accelerating the entry into the mineral fields related to new materials of new energy, optimizing the company’s business layout and highlighting the advantages of its main business.
Ambow’s application for issuing shares to a specific target was approved by the Shanghai Stock Exchange.
Anbotong announced that on September 1st, the company received the review opinions from Shanghai Stock Exchange on the application of the company to issue shares to a specific object by summary procedure: according to the Rules of Shanghai Stock Exchange for the Review of Securities Issuance and Listing of Listed Companies in science and technology innovation board, the application of Beijing Anbotong Technology Co., Ltd. to issue shares to a specific object by summary procedure meets the requirements of issuance, listing and information disclosure.
Yuyuan Co., Ltd. subsidiary participated in the selection and evaluation of real estate projects and was determined as the final implementation subject.
() Announcement, on September 1, 2022, publicized by the Huangpu District People’s Government of Shanghai. Shanghai Fuyou Industrial Development Co., Ltd. ("Fuyou Industrial"), a wholly-owned subsidiary of the company, and Shanghai Yunqi Enterprise Management Consulting Co., Ltd. ("Yunqi Enterprise") recently jointly participated in the historical and cultural scenic spots of the old town in Huangpu District organized by the office of the Leading Group for the Promotion of Historical and Cultural Protection Project in Shanghai. 229-02 plot and 224-04, 224-05, 224-08, 225-03, 225-05, 225-06, 229-03, 229-01 underground space plot historical features protection project implementation subject public selection activities, and after selection and evaluation, it was determined as the final implementation subject, which
Wantong Development: Independent Director Jiang Desong was detained for investigation.
() On the evening of September 1st, it was announced that Jiang Desong, an independent director of the company, was cooperating with the investigation because of his alleged illegal duties, and his spouse showed the company the Notice of Retention issued by the Beijing Municipal Supervision Commission. As of the date of this announcement, due to the fact that relevant matters are still under investigation and there is no conclusion, it is impossible to predict the subsequent normal performance time of Jiang Desong. After a preliminary understanding, the matters involved by Jiang Desong only involve his personal affairs, and have nothing to do with the company. The company’s operation and management are all normal.
Baichuan Energy sends 1.5 yuan date of record every 10 shares every six months for September 7th.
() It is announced that the company will distribute the equity in the first half of 2022, and distribute the cash dividend for every 10 shares (including tax) in 1.5 yuan and date of record on September 7th.
Jichuan Pharmaceutical Co., Ltd. obtained the registration notice of "Qiwei Ciyu Granule"
() Announcement. Recently, Shaanxi Dongke Pharmaceutical Co., Ltd. ("Dongke Pharmaceutical"), a wholly-owned subsidiary of the company, received the Notice of Drug Registration and Filing of Qiwei Ciyu Granules approved and issued by Shaanxi Drug Administration ("Shaanxi Food and Drug Administration").
It is reported that the functions and indications of Qiwei Ciyu Granule are: clearing away heat and promoting diuresis, cooling blood to stop bleeding, removing blood stasis and reducing swelling. It is used for internal hemorrhoids in stage I and II, which belongs to downward flow of damp-heat syndrome according to TCM syndrome differentiation, and the symptoms are bloody stool, anal distension and pain; Red tongue, thin yellow fur, rapid pulse, etc.
Aonong Bio sold 483,600 pigs in August, up 126.64% year-on-year.
() Announcement was issued. In August 2022, the company sold 483,600 pigs, with the sales volume increasing by 12.68% month-on-month and 126.64% year-on-year. At the end of August 2022, the company had 2,128,000 live pigs, an increase of 16.11% compared with the end of August 2021 and an increase of 18.71% compared with the end of December 2021. From January to August, 2022, the company sold a total of 3,256,800 pigs, with a year-on-year increase of 88.76%.
Mykolando spent 483 million yuan to buy back 9.8 million shares.
() Announcement was issued. As of August 31, 2022, the company had repurchased 9.8 million shares, accounting for 1.90% of the total shares of the company, and the total amount paid was RMB 483 million (excluding transaction fees such as commission).
Jiayuan Technology won the 7th Guangdong Provincial Government Quality Award.
Jiayuan Technology announced that recently, the company received the Notice of Guangdong Provincial People’s Government on Commending the Winners of the 7th Guangdong Provincial Government Quality Award issued by Guangdong Provincial People’s Government, and the company won the 7th Guangdong Provincial Government Quality Award.
The company won this honor, which shows that the Guangdong Provincial People’s Government fully affirmed the company’s achievements in product quality management mode, promoting quality management innovation and setting quality benchmarks. Taking this as a new starting point, the company will further improve its product quality and independent innovation ability, enhance its core competitiveness and promote its sustained, healthy and rapid development by continuously deepening quality management and constantly innovating quality management methods.
Aonong Bio: In August, the sales volume of live pigs was 483,600, a year-on-year increase of 126.64%.
Aonong Bio announced on the evening of September 1st that in August, the company sold 483,600 pigs, with the sales volume increasing by 12.68% month-on-month and 126.64% year-on-year. At the end of August, the company had 2,128,000 live pigs, an increase of 16.11% compared with the end of August 2021 and an increase of 18.71% compared with the end of December 2021.
Poly Development successfully issued 500 million yuan of green medium-term notes.
(Reporter Wang Yinhao, Sun Yongzhi) On September 1, () Holding Group Co., Ltd. released the announcement of the issuance results of the fifth green medium-term notes in 2022. The announcement showed that the company successfully issued the fifth green medium-term notes in 2022 on August 31, with a total actual issuance of 500 million yuan, a term of three years and an issuance rate of 2.75%.
Kailuan shares: The controlling shareholder intends to increase its holdings by no more than 2%.
Kailuan shares announced that on September 1, 2022, Kailuan Group, the controlling shareholder, increased its holding of 68,500 shares by centralized bidding, accounting for 0.0043% of the company’s total share capital; It is also planned that within 12 months from the date of this increase, the cumulative number of shares of the company (including this increase) will not exceed 2% of the company’s total share capital.
China xd: The consortium affiliated to the subsidiary signed a contract of 664 million US dollars for overseas EPC projects.
China xd announced that the consortium formed by the wholly-owned subsidiary Xidian International and China Southern Power Grid International Co., Ltd. signed the EPC project contract of Kilo HVDC converter station in Chile with Conexió n Kimallo Aguirre S.A. The winning contract amount was 663,573,900 US dollars, of which Xidian International undertook the contract amount of 425,653,700 US dollars, equivalent to about 2.9 billion yuan, accounting for about the audited operating income of the company in 2021.
Jiang Desong, an independent director of Wantong Development suspected of violating his duty, was detained for investigation.
(Reporter Ma Huanhuan) On the evening of September 1, Vantone Development announced that Jiang Desong, an independent director of the company, was cooperating with the investigation on suspicion of illegal duties and was detained. His spouse showed the company the Notice of Retention issued by the Beijing Municipal Supervision Commission.
Wantong Development said that as of the announcement date, due to the fact that the relevant matters are still under investigation and there is no conclusion, it is temporarily impossible to predict the normal performance time of Jiang Desong. If he is still unable to perform his duties in a short period of time, the board of directors of the company will not rule out taking measures to submit it to the shareholders’ meeting for consideration and re-appointment of independent directors. After a preliminary understanding, the matters involved by Jiang Desong only involve his personal affairs, and have nothing to do with the company. The company’s operation and management are all normal.
41,451,100 restricted shares of Guoli will be listed and circulated on September 13th.
Guoli shares announced that the total number of restricted shares listed and circulated this time was 41.4511 million shares, accounting for 43.45% of the company’s current total shares, and the listing and circulation date was September 13, 2022.
The cumulative reduction ratio of Aiwu Enterprise Management, the controlling shareholder of Laiyifen, exceeds 1%
() Announcement was issued. On September 1, 2022, the company received the Notice Letter on Share Change Reaching 1% from the controlling shareholder Shanghai Aiwu Enterprise Management Co., Ltd. ("Aiwu Enterprise Management"). From April 8, 2021 to October 15, 2021, Aiwu Enterprise Management reduced its holdings by 3,310,600 shares in the secondary market, accounting for 0.98% of the company’s total share capital. From August 31, 2022 to September 1, 2022, the company reduced its holdings by 362,800 shares in the secondary market, accounting for 0.11% of the company’s current total share capital. The total reduction ratio of Aiwu Enterprise Management is 1.09%.
Shengjian Environment signed a subcontract for the process exhaust system of 170 million yuan integrated circuit project.
() Announced. Previously, the company received a Notice of Winning Bid from a domestic semiconductor company, confirming that the company won the bid for "Subcontracting Project of Process Exhaust System of an Integrated Circuit Project", with a total bid price of RMB 170 million (including tax). On September 1st, 2022, the company signed the Subcontracting Project Agreement of Process Exhaust System for an integrated circuit project of a domestic semiconductor company with the contract amount of RMB 170 million (including tax) with the employer.
Yueda Investment, the shareholder of Alte, and the concerted parties intend to reduce their holdings by no more than 3.31% of the shares of the company.
() Announcement: Jiangsu () Co., Ltd. ("yueda Investment"), a shareholder holding 4.1283% of the company’s total shares, and its concerted action, Jiangsu yueda SME Green Development Venture Capital Fund (Limited Partnership) ("Green Fund"), intend to reduce the company’s shares by no more than 16,113,700 shares, with the reduction ratio not exceeding 3.3052% of the company’s total share capital.
Anbotong: The application for issuing shares to a specific target was approved by the Shanghai Stock Exchange.
Anbotong announced that the company received the audit opinion from the Shanghai Stock Exchange, and the company’s application for issuing shares to a specific object in a summary procedure met the issuance conditions, listing conditions and information disclosure requirements.
Samsung Medical: A subsidiary company won the bid for the pre-installed substation project of wind, solar and photovoltaic power plants.
Samsung Medical announced that Aux Hi-Tech, a subsidiary of the company, was recently recommended as a candidate for winning the bid in the 2022-2023 framework procurement of photovoltaic pre-installed substation (Chinese-style, oil transformer) project of China Datang Group Co., Ltd., with an estimated bid amount of about 330 million yuan.
Guoguang Electric’s 3.75% shareholder Bingtou Lianchuang intends to clear the position and reduce its holdings.
Guoguang Electric announced that due to the need of its own funds, Bingtou Lianchuang, a shareholder holding 3.75% shares, plans to reduce its shares in the company through a combination of centralized bidding transactions and block transactions, with a total reduction of no more than 2,903,100 shares, that is, no more than 3.75% of the company’s total share capital.
Guoguang Electric: Bingtou Lianchuang plans to reduce its shareholding by no more than 3.75%.
Guoguang Electric announced on the evening of September 1st that Bingtou Lianchuang, a shareholder holding 3.75% of the shares, intends to reduce the company’s shares by no more than 2,903,100 shares, that is, no more than 3.75% of the company’s total share capital.
Hengrui Pharma: Sevoflurane for inhalation obtained drug registration certificate.
Hengrui Pharma announced on the evening of September 1st that the company had received the Pharmaceutical Registration Certificate for Sevoflurane for Inhalation approved and issued by National Medical Products Administration. The approved indications are the induction and maintenance of general anesthesia in adults and children. Upon inquiry, the global sales of sevoflurane for inhalation in 2021 is about 919 million US dollars. Up to now, the accumulated research and development expenses of sevoflurane-related projects for inhalation are about 14.92 million yuan.
Guoguang Electric shareholders intend to reduce their holdings by no more than 3.75%.
Guoguang Electric announced that the company’s shareholder Bingtou Lianchuang, who holds 3.75% of the shares, intends to reduce the company’s shares by no more than 3.75% of the company’s total share capital.
Ningbo Port: Ningbo Ocean Shipping, a holding subsidiary, was approved for listing.
() On the evening of September 1st, it was announced that Ningbo Ocean Shipping, the company’s holding subsidiary, made an initial public offering of A shares and its application for listing on the main board of Shanghai Stock Exchange was approved by the IEC.
TF Securities: Share repurchase was not implemented in August.
() It was announced on September 1, and in August 2022, the company did not implement share repurchase. By the end of August, 2022, the company had repurchased 67,786,990 A shares through centralized bidding, accounting for 0.7822% of the company’s total share capital. The highest price purchased was RMB 4.01/share, and the lowest price was RMB 3.48/share, and the total amount paid was about RMB 253 million.
Ningbo Port: The IPO application of the holding subsidiary was approved by the Audit Committee of the China Securities Regulatory Commission.
Ningbo Port announced that on September 1, 2022, according to the Announcement of the Audit Results of the 99th Session of the 18th IEC in 2022 issued by the CSRC, Ningbo Ocean Shipping Co., Ltd. (IPO), a holding subsidiary, was approved.
Baichuan Energy will send 1.5 yuan date of record for every 10 shares in the first half of 2022 as September 7.
(Financial News Baichuan Energy announced that the company’s half-year equity distribution implementation plan for 2022 is as follows: based on the total share capital of 1,340,854,800 shares, a cash dividend of RMB 1.50 will be distributed to all shareholders for every 10 shares, and a total cash dividend of RMB 201 million will be distributed, accounting for 81.71% of the net profit returned to the mother in the same period. No bonus shares will be distributed, and no capital reserve will be converted into share capital.
The distribution of rights and interests in date of record is September 7th, and the ex-dividend date is September 8th.
According to the 2022 semi-annual performance report released by Baichuan Energy, the company’s operating income was 2.624 billion yuan, a year-on-year increase of 7.28%; The net profit attributable to shareholders of listed companies was 246 million yuan, a year-on-year decrease of 28.19%; The basic earnings per share was 0.18 yuan, compared with 0.25 yuan in the same period last year.
Baichuan Energy Co., Ltd. mainly engages in urban pipeline gas sales, gas engineering installation and sales in gas appliance. The main services provided by the company are gas sales, gas engineering installation and sales in gas appliance.
(Source: Straight Flush iFinD)
Tongfang intends to publicly transfer the equity of Tongfang Global Life Insurance Co., Ltd.
On the evening of August 31st, () announced that in order to further focus on the main business, recover the non-main business investment and rationally allocate resources, the company intends to transfer 50% equity of Tongfang Global Life Insurance Co., Ltd. (hereinafter referred to as "Tongfang Global Life Insurance"), a shareholding company held by the company, through public listing on the property rights exchange. The initial listing price is not lower than the appraised value (calculated according to the equity ratio) recorded by China National Nuclear Corporation and the company’s capital increase to Tongfang Global Life Insurance after the benchmark date.
According to the announcement, as of June 30, 2022, Tongfang Global Life had total assets of 24.955 billion yuan, total liabilities of 22.009 billion yuan, owners’ equity of 2.946 billion yuan, operating income of 4.137 billion yuan and net profit of 35 million yuan. (He Kui)
Come to Iraq: the controlling shareholder Aiwu Enterprise Management reduced its holding of 3,673,400 shares of the company, with a reduction ratio of 1%.
On the evening of September 1st, the company announced that Aiwu Enterprise Management, the controlling shareholder of the company, recently reduced its holdings by 3,673,400 shares, accounting for 1.09% of the company’s total share capital. After this equity change, Aiwu Enterprise Management’s shares in listed companies decreased from about 190 million shares to 186 million shares, and its shareholding ratio decreased from 56.31% to 55.31%.
Nuohe Zhiyuan’s application for fixed increase was approved by Shanghai Stock Exchange.
Nuohe Zhiyuan announced that on September 1, 2022, the company received the review opinions from the Shanghai Stock Exchange on the application of the company to issue shares to specific objects, and the company’s application for issuing shares to specific objects met the issuance conditions, listing conditions and information disclosure requirements.
Juyi Technology won a 49% stake in Jianghuai UnionPay for 62.4675 million yuan.
Juyi Technology announced that the company participated in bidding for 49% equity of Anhui Jianghuai UnionPay Heavy Construction Machinery Co., Ltd. and successfully bid for the equity at a transaction price of 62.4675 million yuan. This asset purchase is in line with the company’s development strategy, priced according to the evaluation value, and the pricing is fair and reasonable. There is no harm to the interests of the company and shareholders, especially small and medium shareholders, which is conducive to further enhancing the company’s comprehensive competitiveness.
Macalline repurchased 384,800 shares of the company.
On the evening of September 1st, () announced the progress of the company’s share repurchase. The announcement showed that as of August 31st, 2022, the company had repurchased 384,800 A shares through centralized bidding, and the repurchased shares accounted for 0.0088% of the company’s total share capital. The highest purchase price was 5.21 yuan/share, the lowest price was 5.20 yuan/share, and the total amount paid was 2,004,300 yuan.
According to public information, on April 24, 2022, the 43rd interim meeting of the fourth board of directors of Macalline deliberated and passed the Proposal on Deliberating the Share Repurchase of the Company, and agreed that the Company would use its own or self-raised funds of not less than 150 million yuan and not more than 300 million yuan to repurchase the A shares of the Company at a repurchase price of not more than 11.04 yuan/share (hereinafter referred to as "this repurchase"). All the shares repurchased this time will be used for the company’s employee stock ownership plan or equity incentive plan. The repurchase period is no more than 12 months from the date when the repurchase plan is reviewed and approved by the board of directors of the company.
Juyi Technology: won 49% equity of Jianghuai UnionPay for 62.47 million yuan.
Juyi Technology announced on the evening of September 1 that the company participated in bidding for 49% equity of Anhui Jianghuai UnionPay Heavy Construction Machinery Co., Ltd. and successfully bid for the equity at a transaction price of 62.4675 million yuan.
Investigation on Jiang Desong, Independent Director of Vantone Development, Being Liened
Vantone Development announced that the staff of the secretary’s office of the board of directors of the company could not get in touch with Mr. Jiang Desong, the independent director of the company, by telephone or WeChat. After inquiring about the work unit where Mr. Jiang Desong worked, the staff were also told that they could not get in touch with him. It was not until he got in touch with his spouse that he learned that Mr. Jiang Desong, the independent director of the company, was cooperating with the investigation and was detained because of his alleged illegal duties. His spouse also showed the company the Notice of Detention issued by the Beijing Municipal Supervision Commission. As of the date of this announcement, due to the fact that the relevant matters are still under investigation and there is no conclusion, it is impossible to predict the subsequent normal performance time of Mr. Jiang Desong.
Xincheng Holdings has repurchased 2.38 million shares and paid a total of 49.3364 million yuan.
On September 1st, () issued a progress announcement on repurchasing shares by centralized bidding.
According to the announcement, Xincheng Holdings held the 7th meeting of the 3rd Board of Directors on March 29th, 2022 and May 23rd, 2022, respectively, and the 2021 Annual General Meeting of Shareholders deliberated and passed the Proposal on the Share Repurchase Scheme by Centralized Bidding Transaction, agreeing that the company would repurchase the shares of the company by centralized bidding transaction.
The total amount of repurchase funds is not less than RMB 100 million (inclusive) and not more than RMB 200 million (inclusive), and the repurchase price is not more than RMB 41.39/share. The repurchase period is within 6 months from the date when the share repurchase plan is reviewed and approved by the shareholders’ meeting, and the repurchased shares will be cancelled to reduce the registered capital of the company.
The announcement shows that in August 2022, Xincheng Holdings did not implement share repurchase. As of August 31, 2022, the company has repurchased 2.38 million shares, accounting for 0.11% of the company’s total share capital on the date of this announcement. The highest price purchased is 21.10 yuan/share, and the lowest price is 20.20 yuan/share, and the total amount paid is 49.3364 million yuan (excluding transaction costs).
Poly Development issued 500 million yuan of green medium-term notes with an interest rate of 2.75%.
On September 1, Poly Development released the announcement of the issuance results of the fifth green medium-term notes in 2022.
According to the announcement, the bid in this issue is abbreviated as 22 Poly Development MTN005 (Green), with the registered amount of 2.5 billion yuan, the actual total issuance amount of 500 million yuan, the issuance interest rate of 2.75%, the term of three years, the value date of August 31, 2022 and the redemption date of August 31, 2025. The lead underwriter and bookkeeping manager is Industrial Bank Co., Ltd., and the joint lead underwriter is Agricultural Bank of China Co., Ltd.
The winning ticket was issued on August 31st.
